|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Breast-conserving therapy and modified radical mastectomy for primary breast carcinoma:a matched comparative study显示文摘Background:To compare two types of therapy for primary breast carcinoma,breast-conserving therapy(BCT) and modified radical mastectomy(MRM),in a matched cohort study.Methods:A series of 1,746 patients with primary breast cancer treated with BCT or MRM in a single Chinese institute between January 2000 and February 2009 were analyzed retrospectively to compare their outcomes with respect to the incidence of local recurrence(LR),distant metastasis,and survival.The patients were matched with regard to age at diagnosis,spreading to axillary lymph nodes,hormone receptor status,the use of neoadjuvant chemotherapy and maximal tumor diameter.The match ratio was 1:1,and each arm included 873 patients.Results:The median follow-up period was 71 months.The 6-year disease-free survival(DFS) and 6-year distant disease-free survival(DDFS) rates differed significantly between two groups.The 6-year local recurrence-free survival(LRFS) rates were 98.2% [95% confidence interval(CI):0.973-0.989] in the BCT group and 98.7%(95% CI:0.980-0.994) in the MRM group(P=0.182),respectively.DFS rates in BCT and MRM groups were 91.3%(95% CI:0.894-0.932) and 86.3%(95% CI:0.840-0.886)(P<0.001),respectively,whereas the DDFS rates in BCT and MRM groups were 93.6%(95% CI:0.922-0.950) and 87.7%(95% CI:0.854-0.900)(P<0.001),respectively.Conclusions:BCT in eligible patients is as effective as MRM with respect to local tumor control,DFS and DDFS,and may result in a better outcome than MRM in Chinese primary breast cancer patients. | Lize Wang Tao Ouyang Tianfeng Wang Yuntao Xie Zhaoqing Fan Benyao Lin Jinfeng Li | 2015 | Chinese Journal of Cancer Research2015，27，6： | 3 |
| 2 | Association between HER2 status and response to neoadjuvant anthracycline followed by paclitaxel plus carboplatin chemotherapy without trastuzumab in breast cancer显示文摘Background:We recently showed HER2-positive breast cancers are less likely to respond to neoadjuvant anthracycline chemotherapy.Here,we investigated whether HER2-positive breast cancers responded to sequential neoadjuvant anthracycline followed by paclitaxel plus carboplatin regimen in the absence of trastuzumab.Methods:Women(n=372) with operable primary breast cancer initially received two cycles of neoadjuvant anthracyclines,the clinical tumor response was assessed,then patients were received four cycles of paclitaxel plus carboplatin regimen.All the patients did not received trastuzumab treatment in the neoadjuvant setting.HER2 status was determined by immunohistochemistry and/or by fluorescence in situ hybridization in corebiopsy breast cancer tissue obtained before the neoadjuvant chemotherapy.Results:Eighteen percent(67/372) of patients achieved a pathologic complete response(p CR) in their breast.HER2-positive tumors had a significant higher p CR rate than HER2-negative tumors(33.0% versus 13.5%,P<0.001) in this cohort of 372 patients,and positive HER2 status remained an independent favorable predictor of p CR in a multivariate analysis [odds ratio(OR),2.26;95% confidence interval(CI),1.18 to 4.36,P=0.015].Furthermore,patients who responded to initial anthracycline regimens were more likely to respond to paclitaxel plus carboplatin than patients who did not(p CR,27.2% versus 14.6%,P=0.005).Patients with HER2-positive tumors exhibited a significant higher p CR rate than did patients with HER2-negative tumors in both anthracycline response group(40.5% versus 20.0%,P=0.025) and anthracycline non-response group(28.3% versus 11.3%,P=0.002).Conclusions:Under the circumstance of no trastuzumab treatment,women with HER2-positive cancers derive a large benefit from paclitaxel-carboplatin-based neoadjuvant chemotherapy. | Lu Yao Juan Zhang Yiqiang Liu Tao Ouyang Jinfeng Li Tianfeng Wang Zhaoqing Fan Tie Fan Benyao Lin Yuntao Xie | 2015 | Chinese Journal of Cancer Research2015，27，6： | 3 |
| 3 | Value of pre-treatment biomarkers in prediction of response to neoadjuvant endocrine therapy for hormone receptor-positive postmenopausal breast cancer显示文摘Objective: To determine the predictive ability of biomarkers for responses to neoadjuvant endocrine therapy (NET) in postmenopausal breast cancer. Methods: Consecutive 160 postmenopausal women with T 1-3 N 0-1 M 0 hormone receptor (HR)-positive invasive breast cancer were treated with anastrozole for 16 weeks before surgery. New slides of tumor specimens taken before and after treatment were conducted centrally for biomarker analysis and classified using the Applied Imaging Ariol MB-8 system. The pathological response was evaluated using the Miller & Payne classification. The cell cycle response was classified according to the change in the Ki67 index after treatment. Multivariable logistic regression analysis was used to calculate the combined index of the biomarkers. Receiver operating characteristic (ROC) curves were used to determine whether parameters may predict response. Results: The correlation between the pathological and cell cycle responses was low (Spearman correlation coefficient =0.241, P<0.001; Kappa value =0.119, P=0.032). The cell cycle response was significantly associated with pre-treatment estrogen receptor (ER) status (P=0.001), progesterone receptor (PgR) status (P<0.001), human epidermal growth factor receptor 2 (Her-2) status (P=0.050) and the Ki67 index (P<0.001), but the pathological response was not correlated with these factors. Pre-treatment ER levels [area under the curve (AUC) =0.634, 95% confidence interval (95% CI), 0.534-0.735, P=0.008] and combined index of pre-treatment ER and PgR levels (AUC =0.684, 95% CI, 0.591-0.776, P<0.001) could not predict the cell cycle response, but combined index including per-treatment ER/PR/Her-2/Ki67 expression levels could (AUC =0.830, 95% CI, 0.759-0.902, P<0.001). Conclusions: The combined use of pre-treatment ER/PgR/Her-2/Ki67 expression levels, instead of HR expression levels, may predict the cell cycle response to NET. | Min Ying Yingjian He Meng Qi Bin Dong Aiping Lu Jinfeng Li Yuntao Xie Tianfeng Wang Benyao Lin Tao Ouyang | 2013 | Chinese Journal of Cancer Research2013，25，4： | 2 |
| 4 | Association of SIPA1545 C>T polymorphism with survival in Chinese women with metastatic breast cancer显示文摘It has been demonstrated that single nucleotide polymorphisms(SNPs)of SIPA1(signal-induced proliferation associated gene 1)are associated with metastatic efficiency in both human and rodents.The purpose of this study was to determine whether SIPA1545 C>T polymorphism was associated with overall survival in patients with metastatic breast cancer.In this study,SIPA1545 C>T polymorphism was detected in 185 metastatic breast cancer patients using polymerase chain reaction-restriction fragment length polymorphism assay(PCR-RFLP).Survival curves for patients with SIPA1545 C>T polymorphism was compared using the Kaplan-Meier method with log-rank tests.We found that SIPA1545 C>T polymorphism was significantly associated with survival in 185 patients with metastatic breast cancer.Patients with SIPA1545 T/T genotype had a significantly worse overall survival(OS)than did patients with C/T or C/C genotype(50.0%vs.62.9%,P=0.042).Moreover,in multivariate analysis,as compared with the C/C or C/T genotype,the T/T genotype remained an independent unfavorable prognostic marker of OS in this cohort(hazard ratio[HR]=2.16;95%CI=1.12–4.15;P=0.022).Our findings indicate that metastatic breast cancer patients with SIPA1545 T/T genotype have a poorer survival compared to patients with C/C or C/T genotype. | Renling Pei Ye Xu Yan Wei Tao Ouyang Jinfeng Li Tianfeng Wang Zhaoqing Fan Tie Fan Benyao Lin Yuntao Xie | 2013 | Frontiers of Medicine2013，7，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员